FULL YEAR HIGHLIGHTS
Solid financial performance:
Group revenues up 50.0% supported mainly by accelerated ARPU growth, and strong subscriber net add performance as well as the contribution of the digital
Gainers
Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.
SOCAR Türkiye and Turkcell Iletisim Hizmetleri AS (NYSE: TKC) collaborated for the digital transformation of the Aliağa Peninsula, a leading refiney of Türkiye.